These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9266420)

  • 1. Role of interferons in demyelinating disease.
    Johnson KP
    J Neural Transm Suppl; 1997; 49():111-5. PubMed ID: 9266420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of interferons in demyelinating diseases.
    Arnason BG; Toscas A; Dayal A; Qu Z; Noronha A
    J Neural Transm Suppl; 1997; 49():117-23. PubMed ID: 9266421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon beta-1b for the treatment of multiple sclerosis.
    Petri T; Weber-Diehl F
    J Biotechnol; 1995 Nov; 43(1):74-5. PubMed ID: 8573325
    [No Abstract]   [Full Text] [Related]  

  • 4. Nursing management of MS patients receiving interferon beta-1b therapy.
    Costello K; Conway K
    Rehabil Nurs; 1997; 22(2):62-6, 81. PubMed ID: 9110845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.
    Stone LA; Frank JA; Albert PS; Bash CN; Calabresi PA; Maloni H; McFarland HF
    Neurology; 1997 Sep; 49(3):862-9. PubMed ID: 9305355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer versus older treatments for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B; Cohen JA
    Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interferon-beta 1b clinical trial and its implications for other trials.
    Paty DW
    Ann Neurol; 1994; 36 Suppl():S113-4. PubMed ID: 8017869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon beta treatment for multiple sclerosis: persisting questions.
    Goodkin DE
    Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
    Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
    Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
    Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferons in multiple sclerosis. A review of the evidence.
    Panitch HS
    Drugs; 1992 Dec; 44(6):946-62. PubMed ID: 1282865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL; Scott LJ
    CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon beta-1b.
    Goodkin DE
    Lancet; 1994 Oct; 344(8929):1057-60. PubMed ID: 7934448
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferon beta-1B--hope or hype?
    Drug Ther Bull; 1996 Feb; 34(2):9-11. PubMed ID: 8819985
    [No Abstract]   [Full Text] [Related]  

  • 15. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL; Scott LJ
    BioDrugs; 2004; 18(5):343-7. PubMed ID: 15377176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New tools for biotech product development.
    Quay S
    Biotechnology (N Y); 1995 Apr; 13(4):319-20. PubMed ID: 9678946
    [No Abstract]   [Full Text] [Related]  

  • 17. Multiple sclerosis and interferon beta-1b, past, present and future.
    Horowski R
    Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
    [No Abstract]   [Full Text] [Related]  

  • 18. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.
    Rice GP; Paszner B; Oger J; Lesaux J; Paty D; Ebers G
    Neurology; 1999 Apr; 52(6):1277-9. PubMed ID: 10214759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.
    Brod SA; Marshall GD; Henninger EM; Sriram S; Khan M; Wolinsky JS
    Neurology; 1996 Jun; 46(6):1633-8. PubMed ID: 8649562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.